Frankfurt - Delayed Quote EUR

Sernova Biotherapeutics Inc (PSH0.F)

0.1250
-0.0030
(-2.34%)
As of May 16 at 8:02:18 AM GMT+2. Market Open.
Loading Chart for PSH0.F
  • Previous Close 0.1280
  • Open 0.1250
  • Bid --
  • Ask --
  • Day's Range 0.1250 - 0.1250
  • 52 Week Range 0.0905 - 0.2722
  • Volume 4,373
  • Avg. Volume 5,608
  • Market Cap (intraday) 42.057M
  • Beta (5Y Monthly) 1.13
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0600
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. The comoany was formerly known as Sernova Corp. and changed its name to Sernova Biotherapeutics Inc in February 2025. Sernova Biotherapeutics Inc is headquartered in London, Canada.

www.sernova.com

17

Full Time Employees

October 31

Fiscal Year Ends

Recent News: PSH0.F

View More

Performance Overview: PSH0.F

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

PSH0.F
13.49%
S&P/TSX Composite index (^GSPTSE)
5.49%

1-Year Return

PSH0.F
49.27%
S&P/TSX Composite index (^GSPTSE)
16.47%

3-Year Return

PSH0.F
89.20%
S&P/TSX Composite index (^GSPTSE)
28.53%

5-Year Return

PSH0.F
20.66%
S&P/TSX Composite index (^GSPTSE)
77.42%

Compare To: PSH0.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PSH0.F

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    42.06M

  • Enterprise Value

    41.63M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -152.63%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -28.14M

  • Diluted EPS (ttm)

    -0.0600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.21M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -8.11M

Research Analysis: PSH0.F

View More

Company Insights: PSH0.F

Research Reports: PSH0.F

View More